NZ564369A - 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases - Google Patents

5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases

Info

Publication number: NZ564369A
Authority: NZ; New Zealand
Prior art keywords: methyl; portal; liver; hepatic; propyl
Prior art date: 2005-06-10

Application number

NZ564369A

Other languages

English (en)

Inventor

Seul Min Choi

Byoung Ok Ahn

Moohi Yoo

Original Assignee

Dong A Pharm Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-06-10

Filing date

2005-10-21

Publication date

2010-03-26

2005-10-21 Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd

2010-03-26 Publication of NZ564369A publication Critical patent/NZ564369A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Physical Education & Sports Medicine (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NZ564369A 2005-06-10 2005-10-21 5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases NZ564369A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20050050033		2005-06-10
PCT/KR2005/003526 WO2006132460A1 (en)	2005-06-10	2005-10-21	Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative

Publications (1)

Publication Number	Publication Date
NZ564369A true NZ564369A (en)	2010-03-26

Family

ID=37498629

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NZ564369A NZ564369A (en)	2005-06-10	2005-10-21	5-[2-propyloxy-5(1-methyl-2-pyrrolidinylethylamidosulphonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidin-7-one for the prevention and treatment of liver diseases

Country Status (22)

Country	Link
US (1)	US8796286B2 (pt)
EP (1)	EP1888074B1 (pt)
JP (1)	JP4879977B2 (pt)
KR (1)	KR100914445B1 (pt)
CN (1)	CN101193636B (pt)
AT (1)	ATE537832T1 (pt)
AU (1)	AU2005332719B2 (pt)
BR (1)	BRPI0520209A2 (pt)
CA (1)	CA2611638C (pt)
CY (1)	CY1112637T1 (pt)
DK (1)	DK1888074T3 (pt)
ES (1)	ES2376628T3 (pt)
HK (1)	HK1119596A1 (pt)
IL (1)	IL187678A (pt)
MX (1)	MX2007015365A (pt)
NO (1)	NO20076053L (pt)
NZ (1)	NZ564369A (pt)
PT (1)	PT1888074E (pt)
RU (1)	RU2369392C2 (pt)
UA (1)	UA86528C2 (pt)
WO (1)	WO2006132460A1 (pt)
ZA (1)	ZA200800180B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE529127T1 (de) *	2006-12-28	2011-11-15	Insect Biotech Co Ltd	Pharmazeutische zusammensetzung mit arazym zur prävention von leberfunktionsstörung
WO2010118367A2 (en) *	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Antiviral pyrimidines
CA2805110A1 (en) *	2010-07-14	2012-01-19	Cumberland Emerging Technologies, Inc.	Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
JP6235583B2 (ja) *	2012-07-11	2017-11-22	ユニバーシティーオブミシシッピメディカルセンター	画像獲得データから肝線維症を検出及びステージ決定する方法
EP3142655B1 (en)	2014-05-16	2020-12-02	Cumberland Pharmaceuticals Inc.	Compositions and methods of treating cardiac fibrosis with ifetroban
WO2017004040A1 (en)	2015-06-30	2017-01-05	Cumberland Pharmaceuticals, Inc.	Thromboxane receptor antagonists in aerd/asthma
US10064845B2 (en)	2016-05-11	2018-09-04	Cumberland Pharmaceuticals, Inc.	Compositions and methods of treating muscular dystrophy with thromboxane-A2 receptor antagonists
CN110833556A (zh) *	2018-08-15	2020-02-25	广西梧州制药（集团）股份有限公司	吡唑并嘧啶衍生物在治疗肝纤维化的用途
CN113493459B (zh) *	2020-04-07	2022-12-13	广州白云山医药集团股份有限公司白云山制药总厂	Pde5抑制剂化合物及其制备方法和应用
AU2022325803A1 (en) *	2021-08-13	2024-03-28	Goldberg, David J.	Methods and compositions for treating fibrotic liver conditions, using udenafil compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100353014B1 (ko) *	1998-11-11	2002-09-18	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
KR100377782B1 (ko)	2000-06-23	2003-03-29	동아제약 주식회사	발기부전 치료에 효과를 갖는 피라졸로피리미디논화합물의 제조방법
GB0202254D0 (en) *	2002-01-31	2002-03-20	Pfizer Ltd	Prevention of scarring
US20030216407A1 (en) *	2002-01-31	2003-11-20	Pfizer Inc.	Use of PDE5 inhibitors in the treatment of scarring
EP1336602A1 (en)	2002-02-13	2003-08-20	Giovanni Scaramuzzino	Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0214784D0 (en) *	2002-06-26	2002-08-07	Pfizer Ltd	Novel combination
AU2003286555A1 (en)	2002-10-22	2004-05-13	Harbor-Ucla Research And Education Institute	Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases
WO2004108662A1 (ja)	2003-05-15	2004-12-16	Kumiai Chemical Industry Co., Ltd.	フェニルスルホニルカーバメイト誘導体及び農園芸用植物病害防除剤
DE10325813B4 (de)	2003-06-06	2007-12-20	Universitätsklinikum Freiburg	Prophylaxe und/oder Therapie bei der portalen Hypertonie
JP2006527257A (ja) *	2003-06-10	2006-11-30	ファイザー・インク	月経困難症の治療用のｐｄｅ阻害剤及びバソプレッシン受容体アンタゴニストを含んでなる療法組合せ
DE102005001989A1 (de)	2005-01-15	2006-07-20	Bayer Healthcare Ag	Intravenöse Formulierungen von PDE-Inhibitoren

2005
- 2005-10-21 RU RU2007149474/15A patent/RU2369392C2/ru active
- 2005-10-21 CN CN2005800500656A patent/CN101193636B/zh not_active Expired - Fee Related
- 2005-10-21 ES ES05808627T patent/ES2376628T3/es active Active
- 2005-10-21 NZ NZ564369A patent/NZ564369A/en not_active IP Right Cessation
- 2005-10-21 BR BRPI0520209-4A patent/BRPI0520209A2/pt not_active IP Right Cessation
- 2005-10-21 CA CA2611638A patent/CA2611638C/en not_active Expired - Fee Related
- 2005-10-21 WO PCT/KR2005/003526 patent/WO2006132460A1/en active Application Filing
- 2005-10-21 UA UAA200713931A patent/UA86528C2/uk unknown
- 2005-10-21 MX MX2007015365A patent/MX2007015365A/es active IP Right Grant
- 2005-10-21 AT AT05808627T patent/ATE537832T1/de active
- 2005-10-21 AU AU2005332719A patent/AU2005332719B2/en not_active Ceased
- 2005-10-21 EP EP05808627A patent/EP1888074B1/en active Active
- 2005-10-21 DK DK05808627.3T patent/DK1888074T3/da active
- 2005-10-21 US US11/916,752 patent/US8796286B2/en active Active
- 2005-10-21 KR KR1020050099900A patent/KR100914445B1/ko active IP Right Grant
- 2005-10-21 PT PT05808627T patent/PT1888074E/pt unknown
- 2005-10-21 JP JP2008515614A patent/JP4879977B2/ja not_active Expired - Fee Related
2007
- 2007-11-26 NO NO20076053A patent/NO20076053L/no not_active Application Discontinuation
- 2007-11-27 IL IL187678A patent/IL187678A/en not_active IP Right Cessation
2008
- 2008-01-08 ZA ZA200800180A patent/ZA200800180B/xx unknown
- 2008-11-27 HK HK08112976.5A patent/HK1119596A1/xx not_active IP Right Cessation
2012
- 2012-03-14 CY CY20121100272T patent/CY1112637T1/el unknown

Also Published As

Publication number	Publication date
EP1888074B1 (en)	2011-12-21
AU2005332719A1 (en)	2006-12-14
CY1112637T1 (el)	2016-02-10
DK1888074T3 (da)	2012-01-23
HK1119596A1 (en)	2009-03-13
WO2006132460A1 (en)	2006-12-14
US20080207646A1 (en)	2008-08-28
UA86528C2 (uk)	2009-04-27
RU2369392C2 (ru)	2009-10-10
EP1888074A4 (en)	2010-06-23
JP2008543748A (ja)	2008-12-04
CA2611638C (en)	2010-08-24
CN101193636B (zh)	2011-12-28
CA2611638A1 (en)	2006-12-14
CN101193636A (zh)	2008-06-04
JP4879977B2 (ja)	2012-02-22
BRPI0520209A2 (pt)	2009-04-22
ZA200800180B (en)	2009-01-28
RU2007149474A (ru)	2009-07-20
ATE537832T1 (de)	2012-01-15
IL187678A0 (en)	2008-11-03
PT1888074E (pt)	2012-03-01
ES2376628T3 (es)	2012-03-15
KR20060128605A (ko)	2006-12-14
NO20076053L (no)	2008-02-27
KR100914445B1 (ko)	2009-08-28
IL187678A (en)	2013-04-30
MX2007015365A (es)	2008-02-12
AU2005332719B2 (en)	2010-05-13
EP1888074A1 (en)	2008-02-20
US8796286B2 (en)	2014-08-05

Legal Events

Date	Code	Title	Description
2010-07-30	PSEA	Patent sealed
2010-09-30	RENW	Renewal (renewal fees accepted)
2012-10-26	RENW	Renewal (renewal fees accepted)
2015-10-30	RENW	Renewal (renewal fees accepted)	Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 OCT 2016 BY CPA GLOBAL Effective date: 20151012
2017-04-28	LAPS	Patent lapsed

Publication	Publication Date	Title
AU2005332719B2 (en)	2010-05-13	Agent for the prevention and treatment of liver diseases containing pyrazolopyrimidine derivative
TWI336702B (en)	2011-02-01	Benzimidazole derivative and use thereof
JP4698681B2 (ja)	2011-06-08	アミノピリミジン類の化合物及びその塩の調製方法と薬物の用途
US8772326B2 (en)	2014-07-08	Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
UA80756C2 (en)	2007-10-25	Antineoplastic combinations of rapomicine and interferon alfa (?) in the treatment of neoplasms
US20190328734A1 (en)	2019-10-31	Use of Sanglifehrin Macrocyclic Analogues as Anticancer Compounds
CN110049764A (zh)	2019-07-23	用于治疗肾脏疾病或病症的联苯磺酰胺化合物
KR101191068B1 (ko)	2012-10-15	항섬유제로서의 알파ｖ베타3 및 알파ｖ베타6 인테그린길항제
CN101146541A (zh)	2008-03-19	用于治疗中枢神经***疾病的方法和组合物
JP2022062115A (ja)	2022-04-19	ｓＧＣ刺激剤のリンプロドラッグ
TWI248931B (en)	2006-02-11	Pharmaceutical composition for regeneration of cirrhotic liver
EP1452176A1 (en)	2004-09-01	Insulin resistance improving agents
CN1968686B (zh)	2013-01-16	脒腙盐、组合物、制备方法和使用方法
CA2813719A1 (en)	2012-04-12	Methods of use of small molecule modulators of hepatocyte growth factor (scatter factor) activity
US8791117B2 (en)	2014-07-29	Cyclic glycyl-2-allyl proline improves cognitive performance in impaired animals
JP2014515026A (ja)	2014-06-26	アカデシン誘導体、それを含有する製剤および組成物、その治療目的での使用、ならびにその合成法
CN100438911C (zh)	2008-12-03	体重增加抑制剂
KR20010041204A (ko)	2001-05-15	사구체신염의 치료 방법 및 수단
US20230277447A1 (en)	2023-09-07	Targeted release rifaximin compositions
CN101107219A (zh)	2008-01-16	用于治疗尿失禁的化合物
KR100860326B1 (ko)	2008-09-25	에포틸론 ｂ를 함유하는 혈관재협착 예방 및 치료제
CN116650490A (zh)	2023-08-29	化合物mt-1207在降低尿酸方面的应用
Lennernas	2000	Human perfusion studies
WO2004073717A1 (ja)	2004-09-02	血管新生促進剤